Puma Biotechnology (NASDAQ:PBYI)‘s stock had its “buy” rating reissued by stock analysts at Citigroup in a report issued on Wednesday. They currently have a $164.00 price objective on the biopharmaceutical company’s stock. Citigroup’s target price would suggest a potential upside of 77.01% from the stock’s current price.

A number of other analysts have also recently commented on PBYI. Barclays started coverage on shares of Puma Biotechnology in a report on Wednesday, September 6th. They set an “overweight” rating and a $103.00 target price for the company. BidaskClub raised shares of Puma Biotechnology from a “hold” rating to a “buy” rating in a report on Friday, September 8th. Credit Suisse Group upped their target price on shares of Puma Biotechnology from $118.00 to $136.00 and gave the company an “outperform” rating in a report on Monday, September 11th. Stifel Nicolaus upped their target price on shares of Puma Biotechnology from $110.00 to $130.00 and gave the company a “buy” rating in a report on Monday, October 2nd. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating and set a $131.00 target price on shares of Puma Biotechnology in a report on Wednesday, October 4th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $130.67.

Shares of Puma Biotechnology (NASDAQ:PBYI) traded down $6.20 during trading on Wednesday, reaching $92.65. 985,800 shares of the company were exchanged, compared to its average volume of 758,500. The company has a market capitalization of $3,540.00, a P/E ratio of -11.31 and a beta of 0.72. Puma Biotechnology has a 12 month low of $28.35 and a 12 month high of $136.90.

Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) EPS for the quarter, beating the Zacks’ consensus estimate of ($2.50) by $0.43. The business had revenue of $6.10 million for the quarter, compared to analysts’ expectations of $3.78 million. During the same period in the prior year, the company posted ($1.11) earnings per share. analysts predict that Puma Biotechnology will post -8.19 EPS for the current year.

In related news, insider Charles R. Eyler sold 1,322 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $105.46, for a total transaction of $139,418.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 21.10% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of PBYI. Barclays PLC grew its stake in Puma Biotechnology by 453.2% during the first quarter. Barclays PLC now owns 3,961 shares of the biopharmaceutical company’s stock valued at $115,000 after acquiring an additional 3,245 shares in the last quarter. Teacher Retirement System of Texas lifted its position in Puma Biotechnology by 13.7% during the second quarter. Teacher Retirement System of Texas now owns 3,848 shares of the biopharmaceutical company’s stock valued at $115,000 after purchasing an additional 465 shares during the last quarter. Strs Ohio bought a new position in Puma Biotechnology during the second quarter valued at $122,000. BNP Paribas Arbitrage SA lifted its position in Puma Biotechnology by 112.0% during the third quarter. BNP Paribas Arbitrage SA now owns 2,133 shares of the biopharmaceutical company’s stock valued at $143,000 after purchasing an additional 1,127 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in Puma Biotechnology during the second quarter valued at $146,000. 96.00% of the stock is owned by institutional investors.

WARNING: This story was reported by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/01/03/citigroup-reiterates-buy-rating-for-puma-biotechnology-pbyi.html.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Analyst Recommendations for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.